Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Change in Account Payables (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Change in Account Payables for 10 consecutive years, with -$147000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 12.5% to -$147000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, up 1198.57% year-over-year, with the annual reading at $3.1 million for FY2025, 1198.57% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$147000.0 at Rein Therapeutics, up from -$1.9 million in the prior quarter.
  • The five-year high for Change in Account Payables was $4.9 million in Q2 2025, with the low at -$3.7 million in Q4 2023.
  • Average Change in Account Payables over 5 years is -$103600.0, with a median of -$64000.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables soared 573.96% in 2021, then crashed 4289.47% in 2022.
  • Over 5 years, Change in Account Payables stood at $178000.0 in 2021, then skyrocketed by 335.39% to $775000.0 in 2022, then crashed by 583.35% to -$3.7 million in 2023, then soared by 95.52% to -$168000.0 in 2024, then rose by 12.5% to -$147000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$147000.0, -$1.9 million, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.